



#8

0300

Dkt. 51902-A-PCT-US/ADM/JPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Taka-Aki Sato
U.S. Serial No.: 09/809,920
Filed : March 16, 2001
For : TREX, A NOVEL GENE OF TRAF-INTERACTING
EXT GENE FAMILY AND DIAGNOSTIC AND
THERAPEUTIC USES THEREOF

1185 Ave of the Americas
New York, New York 10036
October 26, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)(3)

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant would like to direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**Exhibit A**) and which were previously cited in connection with the prosecution of U.S. Serial No. 09/156,191 or PCT International Application No. PCT/US99/21654, from which the subject application claims benefit under 35 U.S.C. §120. According to 37 C.F.R. §1.98(d), copies of patents or publications that were previously cited by, or submitted to, the Patent Office in connection with such prior applications need not accompany the Information Disclosure Statement. Accordingly, copies of the following references are not attached to this Information Disclosure Statement:

1. Ahn, J. et al. (1995) "Cloning of the Putative Tumor Suppressor Gene for Hereditary Multiple Exostoses (EXT1)" Nat. Genet. 11: 137-143;

Applicants: Taka-Aki Sato
U.S. Serial No.: 09/809,920
Filed: March 16, 2001
page 2

2. Anderson, W.F. (1998) "Human gene therapy," *Nature* 392 (Supplement): 25-30;
3. Branch, A.D. (1998) "A good antisense molecule is hard to find," *TIBS* 23: 45-50;
4. Cheng, G. and Baltimore, D. (1996) "TANK, a Co-Inducer with TRAF2 of TNF- and CD40L-mediated NF-kappaB Activation," *Genes & Dev.* 10: 963-973;
5. Lee S.Y. et al. (1997) "TRAF-interacting Protein (TRIP): A Novel Component of the Tumor Necrosis Factor Receptor (TNFR)- and CD30-TRAF Signaling Complexes that Inhibits TRAF2-mediated NF-kappa Activation," *J. Exp. Med.* 185: 1275-1285;
6. Lee, S.Y. et al. (1997) "TRAF2 is Essential for JNK but Not NF-kappaB Activation and Regulates Lymphocyte Proliferation and Survival," *Immunity* 7: 703-713;
7. Rothe, M. et al. (1996) "I-TRAF is a Novel TRAF-Interacting Protein that Regulates TRAF-Mediated Signal Transduction," *Proc. Natl. Acad. Sci. USA* 93: 8241-8246;
8. Saito, et al. (1998) "Structure, Chromosomal Location, and Expression Profile of EXTR1 and EXTR2, New Members of the Multiple Exostoses Gene Family. Biochemical and Biophysical Research Communications," *Biochem Biophys. Res. Commun.* 243(1): 61-66;
9. Sato, T. et al. (1995) "A Novel Member of the TRAF Family of Putative Signal Transducing Proteins Binds to the Cytosolic Domain of CD40," *FEBS Letter* 358: 113-118;

Applicants: Taka-Aki Sato
U.S. Serial No.: 09/809,920
Filed: March 16, 2001
page 3


10. Stickens, D. et al (1996) "The EXT2 Multiple Exostoses Gene Defines A Family of Putative Tumor Suppressor Genes," Nat. Genet. 14: 25-32;
11. Van Hul, et al. (1998) "Identification of a Third EXT-like Gene (EXTL3) Belonging to the EXT Gene Family," Genomics 47(2): 230-237;
12. Wise, C.A. et al. (1997) "Identification and Localization of the Gene for EXTL, a Third Member of the Multiple Exostoses Gene Family," Genome Research 7: 10-16;
13. Yeh, W.C. et al. (1997) "Early Lethality, Functional NF-kappaB Activation, and Increases Sensitivity to TNF-Induced Cell Death in TRAF2-Deficient Mice," Immunity 7: 715-725;

If a telephone interview would be of assistance in advancing the prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants: Taka-Aki Sato
U.S. Serial No.: 09/809,920
Filed: March 16, 2001
page 4


Applicant is filing this Information Disclosure Statement under 37 C.F.R. §1.97(b) (3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if a fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.



John P. White
Reg. No. 28,678

10/26/01
Date